Compare LPG & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPG | NUVB |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | 291 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2014 | N/A |
| Metric | LPG | NUVB |
|---|---|---|
| Price | $29.06 | $4.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $35.00 | $11.22 |
| AVG Volume (30 Days) | 559.1K | ★ 4.7M |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | ★ 10.67% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.64 | N/A |
| Revenue | ★ $353,341,476.00 | N/A |
| Revenue This Year | $33.36 | $182.76 |
| Revenue Next Year | N/A | $91.83 |
| P/E Ratio | $11.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.66 | $1.57 |
| 52 Week High | $38.40 | $9.75 |
| Indicator | LPG | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 34.73 | 34.56 |
| Support Level | $24.21 | $4.04 |
| Resistance Level | $29.62 | $5.73 |
| Average True Range (ATR) | 1.30 | 0.32 |
| MACD | -1.03 | -0.04 |
| Stochastic Oscillator | 1.37 | 16.38 |
Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece. IT operates in one reportable segment, the international transportation of LPG.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.